In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity
- PMID: 24678112
- PMCID: PMC3965969
- DOI: 10.1016/j.curtheres.2006.12.004
In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity
Abstract
Background: D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia), has been found to reduce prostatic hyperplasia (PH) induced with testosterone (T), but not PH induced with dihydrotestosterone (DHT), in rodents, suggesting the inhibition of prostate 5α-reductase activity.
Objectives: The aims of this study were to assess whether D-004 inhibits prostate 5α-reductase activity in vitro and to examine the effects of D-004 on enzyme kinetics.
Methods: This experimental study was conducted at the Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana, Cuba. Soluble rat prostate preparations were used as the source of 5α-reductase, and ((3)H)-DHT production was measured to determine prostate 5α-reductase activity. Cell-free rat prostate homogenates were pre-incubated with carboxymethyl cellulose 2% alone (control tubes) or D-004 (0.24-125 μg/mL) suspended in the vehicle (treated tubes) for 10 minutes prior to adding the labeled substrate ((3)H)-T Once the reaction was stopped, sterols were extracted with chloroform and aliquots were applied on silica gel plates developed in benzene-acetone (4:1, v/v). Areas containing DHT were scraped and radioactivity was counted. The median inhibitory concentration (IC50) was determined by measuring the conversion of T to DHT The apparent Michaelis-Menten constant (Km) and Vmax values before and after adding D-004 were determined in kinetic studies using labeled T (0.5-25 μmol/L).
Results: Compared with controls, D-004 significantly and dose-dependently inhibited the enzymatic reaction at doses of 1.95 to 125.0 μg/mL) (all, P < 0.05). The IC50 of D-004 required to inhibit 5a-reductase activity was 2.25 μg/mL. Enzyme inhibition was noncompetitive, since D-004 lowered the Vmax from 15.3 to 10.0 nmol DHT/min · mg(-1) protein, while the Km (4.54 μmol/L) was almost unaffected.
Conclusions: D-004 dose-dependently and noncompetitively inhibited in vitro 5α-reductase activity in soluble fractions of rat prostate. Although the extent of the maximal inhibition was high and the value of IC50 was low, the relevance of such inhibition requires further study in vivo.
Keywords: D-004; free fatty acids; prostate 5α-reductase inhibitors; prostate hyperplasia.
Similar articles
-
Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.Curr Ther Res Clin Exp. 2008 Feb;69(1):65-74. doi: 10.1016/j.curtheres.2008.01.002. Curr Ther Res Clin Exp. 2008. PMID: 24692784 Free PMC article.
-
Effect of D-004, a lipid extract from the Cuban royal palm fruit, on in vitro and in vivo effects mediated by alpha-adrenoceptors in rats.Drugs R D. 2005;6(5):281-9. doi: 10.2165/00126839-200506050-00004. Drugs R D. 2005. PMID: 16128598
-
Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats.Curr Ther Res Clin Exp. 2006 Nov;67(6):406-19. doi: 10.1016/j.curtheres.2006.12.005. Curr Ther Res Clin Exp. 2006. PMID: 24678113 Free PMC article.
-
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.Eur Urol. 2000 Apr;37(4):367-80. doi: 10.1159/000020181. Eur Urol. 2000. PMID: 10765065 Review.
-
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.World J Urol. 2002 Apr;19(6):413-25. doi: 10.1007/s00345-002-0248-5. World J Urol. 2002. PMID: 12022710 Review.
Cited by
-
Role of Phytotherapy in the Management of BPH: A Summary of the Literature.J Clin Med. 2023 Feb 28;12(5):1899. doi: 10.3390/jcm12051899. J Clin Med. 2023. PMID: 36902686 Free PMC article. Review.
-
Analysis of Hydroxy Fatty Acids from the Pollen of Brassica campestris L. var. oleifera DC. by UPLC-MS/MS.J Pharm (Cairo). 2013;2013:874875. doi: 10.1155/2013/874875. Epub 2012 Oct 10. J Pharm (Cairo). 2013. PMID: 26555998 Free PMC article.
-
Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.Ther Adv Urol. 2019 Jun 11;11:1756287219854923. doi: 10.1177/1756287219854923. eCollection 2019 Jan-Dec. Ther Adv Urol. 2019. PMID: 31217822 Free PMC article.
-
D-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats.Transl Androl Urol. 2015 Aug;4(4):391-7. doi: 10.3978/j.issn.2223-4683.2014.03.05. Transl Androl Urol. 2015. PMID: 26816837 Free PMC article.
-
Comparative Study of the Efficacy and Tolerability of Palmex® (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia.Urol Res Pract. 2025 Mar 7;50(5):302-309. doi: 10.5152/tud.2025.24067. Urol Res Pract. 2025. PMID: 40248996 Free PMC article.
References
-
- Clifford G.M., Farmer R.D. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol. 2000;38:2–19. - PubMed
-
- Thorpe A., Neal D. Benign prostatic hyperplasia [published correction appears in Lancet. 2003;362:496] Lancet. 2003;361:1359–1367. - PubMed
-
- Bhargava S., Canda A.E., Chapple C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol. 2004;14:1–6. - PubMed
LinkOut - more resources
Full Text Sources